Abstract
Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cochrane Database of Systematic Reviews |
Udgave nummer | 3 |
Sider (fra-til) | CD005370 |
ISSN | 1469-493X |
DOI | |
Status | Udgivet - 1 jan. 2008 |